ClinicalTrials.gg
RecruitingNCT07719491Updated Sep 23, 2026

Study of GS-0415 and How It Works in People With HIV

A Phase 1 interventional study of GS-0415 and GS-0415 Placebo in HIV -1 Infection, sponsored by Gilead Sciences. Recruiting at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and intravenous (IV) GS-0415 in people with HIV-1 (PWH) on antiretroviral treatment.

The primary objectives of this study are to evaluate the safety and tolerability of escalating, single and multiple subcutaneous (SC) and intravenous (IV) doses of GS-0415, administered in PWH who are virologically suppressed on antiretroviral therapy (ART) and to evaluate the pharmacokinetics (PK) of GS-0415.

02

Conditions studied

  • HIV -1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥ 18 years and age ≤ 65 years at screening
  • On stable antiretroviral (ARV) treatment for ≥ 12 consecutive months prior to screening, throughout the duration of study treatment and follow-up
  • The following ARV agents are not allowed as part of the current ART regimen: entry inhibitors (maraviroc, enfuvirtide, ibalizumab, or fostemsavir)
  • Plasma -1 RNA \< 50 copies/mL for ≥ 12 months before and at screening with at least 2 documented HIV-1 RNA \<50 copies/mL within the last 12 months.
  • Clusters of differentiation 4 (CD4) count ≥ 350 cells/μL
  • Weight ≥ 50 kg and ≤ 110 kg at screening and Day 1
  • (BMI) ≥ 18.5 kg/m2 and ≤ 35 kg/m2 at screening and Day 1

Key Exclusion Criteria:

  • Documented history of pre-ART CD4 nadir \< 100 cells/μL. Unknown pre-ART CD4 nadir is acceptable
  • Known to have initiated ART within 6 months of HIV infection. Unknown time between infection and ART initiation is acceptable
  • Females who are pregnant or breastfeeding or who may wish to become pregnant during the study or within 42 days after last study drug administration
  • Have chronic virus (HBV) as determined by either:

    1. Positive HBV surface antigen, regardless of HBV core antibody status, at the Screening visit
    2. Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the Screening visit
  • Have active virus (HCV) infection:

    1.) Positive anti-HCV antibody and negative HCV polymerase chain reaction (PCR) results are acceptable

  • Have a history of any of the following:

    2.) Significant serious skin disease, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria as assessed by the investigator

    3.) Significant drug sensitivity or drug allergy ('but not limited to anaphylaxis or drug-induced liver injury) as assessed by the investigator

    4.) Known to the study drugs, their metabolites, or to formulation

    5.) Previous or current history of bleeding disorder, disorder including unexplained acute or chronic thrombocytopenia

    6.) diseases including Type 1 diabetes mellitus

    7.) Serious or active medical or psychiatric illness that would interfere with participant treatment, assessment, or compliance with the protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Group A Single Ascending Dose (SAD): GS-0415

    Participants will receive single escalating doses of GS-0415 via subcutaneous (SC) or intravenously (IV) on Day 1.

    Drug: GS-0415

  • Experimental
    Group A SAD: Placebo

    Participants will receive placebo to match the single escalating doses of GS-0415 via SC or IV on Day 1.

    Drug: GS-0415 Placebo

  • Experimental
    Group B SAD: GS-0415

    Participants will receive single escalating doses of GS-0415 via SC or IV on Day 1.

    Drug: GS-0415

  • Experimental
    Group B SAD: Placebo

    Participants will receive placebo to match the single escalating doses of GS-0415 via SC or IV on Day 1.

    Drug: GS-0415 Placebo

  • Experimental
    Group C Multiple Ascending Dose (MAD): GS-0415

    Participants will receive escalating doses of GS-0415 via SC or IV at five different timepoints up to Date 57.

    Drug: GS-0415

  • Experimental
    Group C MAD: Placebo

    Participants will receive placebo to match escalating doses of GS-0415 via SC or IV at five different timepoints up to Day 57.

    Drug: GS-0415 Placebo

Interventions

  • DrugGS-0415

    Administered SC or IV

  • DrugGS-0415 Placebo

    Administered SC or IV

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)

    Time frame: First dose date up to 99 days

  2. Percentage of Participants Experiencing Clinical Laboratory Abnormalities

    Time frame: First dose date up to 99 days

  3. Serum Pharmacokinetic (PK) Parameter (After Single Ascending Dose (SAD)): AUCinf of GS-0145

    AUCinf is defined as the area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).

    Time frame: Up to 43 days

  4. Serum PK Parameters (SAD): Cmax of GS-0145

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Up to 43 days

  5. Serum PK Parameters Multiple Ascending Dose (MAD): Dose 1 and Dose 5: AUCtau of GS-0145

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval.

    Time frame: Up to 99 days

  6. Serum PK Parameters MAD: Dose 1 and Dose 5: Cmax of GS-0145

    Time frame: Up to 99 days

Secondary outcomes

  1. Percentages of participants With of Treatment-Emergent Anti-GS-0415 Antibodies

    Time frame: Up to 99 days

  2. Percentages of participants With Virological Rebound (Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 copies/mL)

    Time frame: Up to 99 days

07

Study locations

15 of 16 sites recruiting
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
    Recruiting
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • Floridian Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33407, United States
    Recruiting
  • Emory University Hospital Midtown Infectious Disease Clinic
    Atlanta, Georgia 30308, United States
    Recruiting
  • Centricity Research CPU - Georgia
    Columbus, Georgia 31904, United States
    Recruiting
  • Indiana CTSI Clinical Research Center
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
    Recruiting
  • PPD Development, LP
    Las Vegas, Nevada 89113, United States
    Recruiting
  • St. Michaels Medical Center
    Newark, New Jersey 07102, United States
    Not yet recruiting
  • Jacobi Medical Center
    The Bronx, New York 10461, United States
    Recruiting
  • Duke Early Phase Clinical Research Unit
    Durham, North Carolina 27710, United States
    Recruiting
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45267, United States
    Recruiting
  • The Ohio State University Medical Center Infectious Diseases Clinic
    Columbus, Ohio 43210, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Aug 2029, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartActual
Jul 22, 2026
Primary completionEst.
Aug 2029
CompletionEst.
Aug 2029
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07719491
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Jul 22, 2026
Primary completion
Aug 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Sep 23, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion